argenx SE reported $1.36B in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
AstraZeneca USD 15.38B 90M Jun/2026
Genmab DKK 1.06B 36M Dec/2025
GlaxoSmithKline GBP 8.41B 781M Jun/2026
GRIFOLS EUR 1.87B 170M Jun/2026
Hikma Pharmaceutical USD 1.69B 863M Dec/2025
Lakefront Biotherapeutics EUR 6.5M 894.32M Mar/2026
Qiagen NV USD 463.12M 43.9M Jun/2026
UCB EUR 4.25B 764M Dec/2025